NCT07685873 · RECRUITING
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
This trial is testing a new PET/CT imaging agent called 18F-FPyCO/SMBT-1, which targets an enzyme called MAO-B, to see how well it can detect and diagnose changes in the brain and body in people with Parkinson's disease or related conditions. The phase is unspecified, meaning this is likely an early feasibility or exploratory imaging study, not a treatment trial. Details beyond the imaging goal are limited.
Eligibility criteria
Inclusion Criteria: - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled TSPO PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-07-06